UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Targeting coagulation activation in severe COVID-19 pneumonia: lessons from bacterial pneumonia and sepsis

José, RJ; Williams, A; Manuel, A; Brown, JS; Chambers, RC; (2020) Targeting coagulation activation in severe COVID-19 pneumonia: lessons from bacterial pneumonia and sepsis. European Respiratory Review , 29 (157) , Article 200240. 10.1183/16000617.0240-2020. Green open access

[thumbnail of 200240.full.pdf]
Preview
Text
200240.full.pdf - Published Version

Download (512kB) | Preview

Abstract

Novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has rapidly spread throughout the world, resulting in a pandemic with high mortality. There are no effective treatments for the management of severe COVID-19 and current therapeutic trials are focused on antiviral therapy and attenuation of hyper-inflammation with anti-cytokine therapy. Severe COVID-19 pneumonia shares some pathological similarities with severe bacterial pneumonia and sepsis. In particular, it disrupts the haemostatic balance, which results in a procoagulant state locally in the lungs and systemically. This culminates in the formation of microthrombi, disseminated intravascular coagulation and multi-organ failure. The deleterious effects of exaggerated inflammatory responses and activation of coagulation have been investigated in bacterial pneumonia and sepsis and there is recognition that although these pathways are important for the host immune response to pathogens, they can lead to bystander tissue injury and are negatively associated with survival. In the past two decades, evidence from preclinical studies has led to the emergence of potential anticoagulant therapeutic strategies for the treatment of patients with pneumonia, sepsis and acute respiratory distress syndrome, and some of these anticoagulant approaches have been trialled in humans. Here, we review the evidence from preclinical studies and clinical trials of anticoagulant treatment strategies in bacterial pneumonia and sepsis, and discuss the importance of these findings in the context of COVID-19.

Type: Article
Title: Targeting coagulation activation in severe COVID-19 pneumonia: lessons from bacterial pneumonia and sepsis
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1183/16000617.0240-2020
Publisher version: https://doi.org/10.1183/16000617.0240-2020
Language: English
Additional information: Copyright © ERS 2020. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Department of Education
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Respiratory Medicine
URI: https://discovery.ucl.ac.uk/id/eprint/10111491
Downloads since deposit
35Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item